Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NCT04068896 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Metastatic Castration-resistant Prostate Cancer
Bladder Cancer
Melanoma
Non-small Cell Lung Cancer
Colorectal Cancer
Gastric Cancer
Esophageal Cancer
Ovarian Cancer
Head Neck Squamous Cell Carcinoma
Prostate Cancer

Interventions

BIOLOGICAL: NGM120 30mg
BIOLOGICAL: NGM120 100mg
BIOLOGICAL: NGM120 30mg with Gemcitabine and Abraxane
BIOLOGICAL: NGM120 100mg with Gemcitabine and Abraxane
BIOLOGICAL: NGM120 100mg Q3W
OTHER: Placebo

Sponsor

NGM Biopharmaceuticals, Inc